{"prompt": "['8.1.6 Mini International Neuropsychiatric Interview', 'The major clinical criterion for inclusion in the study is that the patient be diagnosed with', 'Bipolar I or Bipolar II Disorder, meeting the DSM-5 criteria. The methodology for', 'confirming this diagnosis is the M.I.N.I. International Neuropsychiatric Interview 7.0.2', '(8/8/16 version) by Dr. David V. Sheehan. The M.I.N.I. is a well-validated clinical tool', '(Sheehan et al., 1998). It will be used in this study at screening only to confirm the', 'diagnosis of Bipolar Depression in patients evaluated for inclusion in the study. It will be', 'completed by the investigator or an expert site-based rater approved by the sponsor.', '8.1.7 Columbia Suicide Severity Rating Scale', 'The C-SSRS is a questionnaire developed and validated by Kelly Posner and', 'colleagues (2011) for the assessment of suicidal ideation and behavior. Several', 'versions have been developed including the \"baseline\" and \"screening\" versions and a', 'combined \"baseline/screening\" version of the scale which assesses suicidal ideation', \"and behavior in a patient's lifetime and during a predefined time period. This version\", \"can assess a patient's lifetime suicidality as well as eligibility based on\", 'inclusion/exclusion criteria. A separate \"Since Last Visit\" version of the scale has been', \"developed which is used to assess suicidality since the patient's last visit. This version\", 'is meant to assess patients who have completed at least 1 initial C-SSRS assessment,', 'and should be used in every subsequent visit. The \"Since Last Visit\" version of the C-', 'SSRS addresses any suicidal thoughts or behaviors the patient may have had since the', 'last time the C-SSRS was administered.', 'The C-SSRS will be administered by the investigator or an expert site-based rater, as', 'indicated in the Schedule of Events (Appendix. A).', 'At screening, a patient will not be eligible if he or she reports suicidal ideation of type 4', 'or 5 on the C-SSRS within 6 months prior to screening or any suicidal behavior in the', 'last 2 years prior to screening, as indicated by any \"yes\" answers on the suicidal', 'behavior section of the C-SSRS.', '8.1.8 Young Mania Rating Scale', 'The YMRS is an 11-item, clinician-administered mania rating scale with established', 'reliability, validity, and sensitivity that was designed to assess the severity of manic', 'symptoms (Young et al 1978). Four of the YMRS items are rated on a 0 to 8 scale, with', 'the remaining 7 items rated on a 0 to 4 scale. The total score is appropriate both for', 'assessing baseline severity of manic symptoms and for assessing treatment-emergent', 'manic symptoms in patients with Bipolar I or Bipolar Il Disorder with Depression. It will', 'Intra-Cellular Therapies, Inc. Confidential', '35 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['be completed by the investigator or an expert site-based rater according to Appendix A', '(Schedule of Events).', '8.1.9 Clinical Global Impressions of Severity', 'The Clinical Global Impressions Scale (CGI) has been modified specifically for use in', 'assessing global illness severity and change in patients with Bipolar Disorder', '(Spearing et al 1997). The CGI-BP-S is a standardized assessment tool that a clinician', 'can use to rate the severity of illness, change over time, and efficacy of medication,', \"taking into account the patient's clinical condition and the severity of side effects. The\", \"CGI-BP-S is used to document the clinician's impression of the patient's current illness\", 'state; it will be used in this study at screening (as a criterion for inclusion or exclusion)', 'and throughout the study as a measure of efficacy. Scores on the CGI-BP-S range from', '1 (not ill at all) to 7 (among the most extremely ill). A CGI-BP-S assessment will be', 'completed at screening by the investigator or another ITI-approved expert site-based', 'rater according to Appendix A (Schedule of Events).', '8.2 Efficacy Assessments and Procedures', '8.2.1 MADRS', 'The MADRS is a 10-item checklist designed to measure the overall severity of', 'depressive symptoms (Montgomery and \u00c4sberg, 1979). Individual items are rated by', 'the investigator (or another ITI-approved expert site-based rater) according to Appendix', 'A (Schedule of Events) on a scale of 0 to 6 in which a score of 6 represents the most', 'severe symptoms for each item assessed. The total score ranges from 0 to 60.', 'Remission of Depression based on the MADRS is generally defined as a patient with a', 'MADRS total score of 12 at endpoint. A \"responder\" on the MADRS is defined as a', '>50% reduction from Baseline in total MADRS score at endpoint.', 'The total score on the MADRS at screening is a major criterion for inclusion in the study,', 'as well as the primary outcome measure for the study.', 'Intra-Cellular Therapies, Inc. Confidential', '36 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}